TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10566672

Group type: EXPERIMENTAL
Intervention: Very low calorie diet for 16 weeks followed by a hypocaloric diet for 32 weeks
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Low initial leptin levels and large declines in serum leptin
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Leptin levels (baseline or changes)
Number of subjects: 69
Study: 2193627

Group type: EXPERIMENTAL
Intervention: 1-day doxycycline regimen
Number of subjects: 59

Group type: COMPARATOR
Intervention: 5-day josamycin regimen
Number of subjects: 59
Study: 341689

Group type: EXPERIMENTAL
Intervention: Pyrogastrone (carbenoxolone sodium with alginate antacid) for 8 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (alginate antacid alone, Gaviscon‐like)
Number of subjects: 37
Study: 31981106

Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02%/latanoprost 0.005% fixed combination QD for 3 months
Number of subjects: 415

Group type: COMPARATOR
Intervention: Netarsudil 0.02%
Number of subjects: 415

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 415
Study: 31142366

Group type: EXPERIMENTAL
Intervention: Modified Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Social Interaction and Routine Education (SIRE)
Number of subjects: 100
Study: 28808942

Group type: EXPERIMENTAL
Intervention: Time-sensitive alerts delivered to PCPs' InBaskets
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Alerts for patients with longer hospital stays (>4 days)
Number of subjects: 799

Group type: COMPARATOR
Intervention: Alerts delivered to PCPs with a higher number of notifications at the time of alert delivery
Number of subjects: 799

Group type: COMPARATOR
Intervention: Alerts delivered on Saturdays
Number of subjects: 799
Study: 26537175

Group type: EXPERIMENTAL
Intervention: Sleep improvement intervention based on cognitive behavioral and mindfulness principles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control condition teaching study skills
Number of subjects: 0
Study: 25747685

Group type: EXPERIMENTAL
Intervention: Electronic consent group (n = 32)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Paper-based consent group (n = 30)
Number of subjects: 62
Study: 23071195

Group type: EXPERIMENTAL
Intervention: LSVT(®)LOUD with Companion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Historical treatment group with standard, in-person LSVT LOUD
Number of subjects: 16
Study: 18713796

Group type: EXPERIMENTAL
Intervention: Nasal spray treatment with Streptococcus sanguinis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nasal spray treatment with Lactobacillus rhamnosus
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17505041

Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BVP-ON)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group (BVP-OFF)
Number of subjects: 239
Study: 15240654

Group type: EXPERIMENTAL
Intervention: 200 lux light stimulus for 6.5 hours after prior exposure to 0.5 lux
Number of subjects: 8

Group type: COMPARATOR
Intervention: 200 lux light stimulus for 6.5 hours after prior exposure to 200 lux
Number of subjects: 8
Study: 12074774

Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg once daily
Number of subjects: 1077
Study: 9819038

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) continuous infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) with heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) with low‐molecular‐weight heparin (LMWH, enoxaparin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) with saline solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) continuous infusion systems
Number of subjects: 0
Study: 7806134

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (0.625 mg daily for 21 days) administered at 8 p.m.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conjugated equine estrogens (0.625 mg daily for 21 days) administered at 8 a.m.
Number of subjects: 24
Study: 2595041

Group type: EXPERIMENTAL
Intervention: Criticare 500
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Novametrix 500
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Visual display
Number of subjects: 100
Study: 6778331

Group type: EXPERIMENTAL
Intervention: Pulverized prednisone tablets (5 mg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Concomitant sulfisoxazole suspension of 50 mg/kg/day twice daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Lactose powder (placebo)
Number of subjects: 41
Study: 30991720

Group type: EXPERIMENTAL
Intervention: Sofrito (240 g/70 kg)
Number of subjects: 22
Study: 28391599

Group type: EXPERIMENTAL
Intervention: One-stop-shop with in vivo reflectance confocal microscopy (RCM) imaging followed by direct surgical excision
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard care (planned excision based on histological diagnosis and subtype of a punch biopsy)
Number of subjects: 95
Study: 26336926

Group type: EXPERIMENTAL
Intervention: Overexpression of wild-type p66Shc
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overexpression of mutant p66Shc (Ala36)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects (liver biopsies)
Number of subjects: 0
Study: 23381608

Group type: EXPERIMENTAL
Intervention: StO₂ guided resuscitation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard resuscitation without StO₂ guidance
Number of subjects: 30
Study: 22573022

Group type: EXPERIMENTAL
Intervention: Omalizumab (OT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 53
Study: 20483003

Group type: EXPERIMENTAL
Intervention: Minimally invasive craniopuncture combined with urokinase infusion therapy
Number of subjects: 304

Group type: COMPARATOR
Intervention: Clearance of hematoma by craniotomy with small bone flap
Number of subjects: 304
Study: 17509027

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education
Number of subjects: 0
Study: 16154019

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES) - Cypher (n=264) and Taxus (n=281)
Number of subjects: 826

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS) - Vision (n=281)
Number of subjects: 826

Group type: COMPARATOR
Intervention: Drug-eluting stents (DES) compared to Bare-metal stents (BMS)
Number of subjects: 826
Study: 12115091

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate (SSG) for 10 days
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate (SSG) for 20 days
Number of subjects: 38
Study: 10099909

Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 15000

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 15000
Study: 7555458

Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (De‐Nol)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Antacids, Cimetidine, Ranitidine
Number of subjects: 85
Study: 2190013

Group type: EXPERIMENTAL
Intervention: Amphotericin B at a daily dose of 2,400 mg
Number of subjects: 111

Group type: COMPARATOR
Intervention: Amphotericin B at a daily dose of 1,200 mg
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Amphotericin B at a daily dose of 2,400 to 7,200 mg
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Amphotericin B at a daily dose of 4,800 mg
Number of subjects: 111
Study: 7317219

Group type: EXPERIMENTAL
Intervention: Systemic benzylpenicillin and flucloxacillin administered just before operation and one and six hours afterwards.
Number of subjects: 431

Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 431
Study: 31835186

Group type: EXPERIMENTAL
Intervention: Alcohol (Males: 0.68 g/kg; Females: 0.60 g/kg)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 30758295

Group type: EXPERIMENTAL
Intervention: Supportive education parenting program (2 phone-based perinatal educational sessions, 1 phone-based educational session after childbirth, 1-month postpartum access to a mobile health app)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (standard hospital care)
Number of subjects: 16
Study: 29180855

Group type: EXPERIMENTAL
Intervention: 0.025% capsaicin ointment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25785658

Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.5‐1.5 IU/h) as a continuous subcutaneous insulin infusion (CSII) during transient hyperglycemia for 2 h (visit TH)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.5‐1.5 IU/h) as a continuous subcutaneous insulin infusion (CSII) during continuous hyperglycemia for 12 h (visit CH)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.5‐1.5 IU/h) as a continuous subcutaneous insulin infusion (CSII) during both visits
Number of subjects: 8

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 8
Study: 24048581

Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (traditional therapy)
Number of subjects: 60
Study: 21466532

Group type: EXPERIMENTAL
Intervention: Etanercept plus narrowband ultraviolet B (NB-UVB) phototherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etanercept monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etanercept plus NB-UVB
Number of subjects: 0
Study: 20491143

Group type: EXPERIMENTAL
Intervention: Conservative (restrictive) infusion strategy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Liberal (traditional) infusion strategy
Number of subjects: 2
Study: 17298695

Group type: EXPERIMENTAL
Intervention: CLA-supplemented yoghurt-like product
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo yoghurt
Number of subjects: 44
Study: 14662708

Group type: EXPERIMENTAL
Intervention: ADMA infusion at a dose of 0.25 mg ADMA x kg(‐1) x min(‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N(G)-nitro-L-arginine methyl ester infusion at a dose of 3 microg x kg(‐1) x min(‐1)
Number of subjects: 0
Study: 11703963

Group type: EXPERIMENTAL
Intervention: Active treatment with low-fat foods enriched with 1.25 to 5.0 g/day of nonesterified plant sterols and mineral nutrients (calcium, magnesium, potassium)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo group with corresponding placebo food items
Number of subjects: 78
Study: 9390726

Group type: EXPERIMENTAL
Intervention: R-(+)- and S-(-)-remoxipride
Number of subjects: 0
Study: 7911009

Group type: EXPERIMENTAL
Intervention: Acrivastine (8 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3309653

Group type: EXPERIMENTAL
Intervention: Sodium chloride (240 mmol per day for 7 days)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Sodium citrate (equimolar amount to sodium chloride)
Number of subjects: 5
Study: 29798795

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 259

Group type: COMPARATOR
Intervention: Escalated antiarrhythmic drug therapy
Number of subjects: 259
Study: 27499622

Group type: EXPERIMENTAL
Intervention: Proretinal nanoparticles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retinoic acid (RA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free retinal
Number of subjects: 0
Study: 25707921

Group type: COMPARATOR
Intervention: AUSDRISK score group 12-15
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: AUSDRISK score group ≥ 20
Number of subjects: 209

Group type: COMPARATOR
Intervention: Overall sample
Number of subjects: 209
Study: 23092785

Group type: EXPERIMENTAL
Intervention: Rifaximin plus fibre supplementation (400 mg b.d. for one week per month + 3.5 g high-fibre supplementation b.d.)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Fibre supplementation alone (3.5 g high-fibre supplementation b.d.)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Rifaximin plus fibre supplementation
Number of subjects: 165
Study: 20525840

Group type: COMPARATOR
Intervention: Celecoxib 200 mg daily
Number of subjects: 662

Group type: COMPARATOR
Intervention: Glucosamine 500 mg three times daily
Number of subjects: 662

Group type: COMPARATOR
Intervention: Combination glucosamine and chondroitin sulphate
Number of subjects: 662

Group type: COMPARATOR
Intervention: Chondroitin sulphate 400 mg three times daily
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 662
Study: 18986748

Group type: COMPARATOR
Intervention: Immediate defibrillation
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: CPR first
Number of subjects: 202
Study: 15631561

Group type: EXPERIMENTAL
Intervention: Behaviorally oriented cardiac rehabilitation and secondary prevention program focusing on lifestyle changes (smoking, diet, exercise, stress); n=46
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Behaviorally oriented cardiac rehabilitation and secondary prevention program; n=46
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard-care control group; n=42
Number of subjects: 88
Study: 11818769

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: R(‐)‐ketamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Racemic ketamine
Number of subjects: 24
Study: 10519500

Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine (1.5%)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intra-articular saline
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (250 microg/kg bolus followed by 13 microg x kg(‐1) x h(‐1) infusion)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intravenous saline (equivalent volume to lidocaine)
Number of subjects: 74
Study: 7492104

Group type: EXPERIMENTAL
Intervention: A77003 at 0.035 mg/kg/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: A77003 at 0.07 mg/kg/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: A77003 at 0.14 mg/kg/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: A77003 at 0.28 mg/kg/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All dosage groups
Number of subjects: 0
Study: 1826989

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia
Number of subjects: 186

Group type: COMPARATOR
Intervention: Sufentanil anesthesia
Number of subjects: 186
Study: 6182516

Group type: EXPERIMENTAL
Intervention: Oral combined preparation (antihistamine + decongestant)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 31407802

Group type: EXPERIMENTAL
Intervention: 0.5% G. speciosum ethanolic extract (GSE) serum applied for 56 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 24
Study: 30292773

Group type: EXPERIMENTAL
Intervention: Telephone support for breastfeeding provided by certified and trained promotoras
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no telephone support)
Number of subjects: 61
Study: 26761023

Group type: EXPERIMENTAL
Intervention: Risk‐Seeking priming condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk‐Aversive priming condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control priming condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Working memory assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 0
Study: 25085517

Group type: EXPERIMENTAL
Intervention: CMT Neuropathy Score (CMTNS) components including Ulnar compound motor action potential (CMAP), leg motor symptoms, arm motor symptoms, leg strength, and sensory symptoms
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: 10m-timed walking test (T10MW)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: 9 hole-peg test (9HPT)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Foot dorsal flexion dynamometry
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Composite of eight components (CMAP, Motor symptoms legs, Motor symptoms arms, Strength of Legs, Sensory symptoms)
Number of subjects: 479
Study: 22298375

Group type: EXPERIMENTAL
Intervention: PAE + resin-modified glass ionomer cement (RMGIC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PAE + composite resin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluoridated toothpaste
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Non-fluoridated toothpaste
Number of subjects: 30

Group type: COMPARATOR
Intervention: 37% phosphoric acid-etching (PAE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (negative control)
Number of subjects: 30
Study: 19653747

Group type: EXPERIMENTAL
Intervention: Motivationally significant stimuli (faces and facial threat)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel temporal order judgment (TOJ) paradigm without cues
Number of subjects: 0
Study: 16339292

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 12789177

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B further diluted with preservative-containing saline
Number of subjects: 15

Group type: COMPARATOR
Intervention: Botulinum toxin type B further diluted with preservative-free saline
Number of subjects: 15
Study: 10957865

Group type: EXPERIMENTAL
Intervention: Lumpectomy plus irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conservative surgery plus radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 Gy boost to the tumor bed after 50 Gy to the whole breast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole breast irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irradiation of supraclavicular lymph nodes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irradiation of parasternal lymph nodes
Number of subjects: 0
Study: 8653163

Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 120

Group type: COMPARATOR
Intervention: Right lateral position
Number of subjects: 120

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Venous pH in left lateral position
Number of subjects: 120

Group type: COMPARATOR
Intervention: Venous pH in right lateral position
Number of subjects: 120

Group type: COMPARATOR
Intervention: Venous pH in supine position
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Position effects on pH, PaCO2, bicarbonate
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Position effects on PvO2, PvCO2, bicarbonate, venous saturation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Calculated arterial-venous oxygen difference
Number of subjects: 120
Study: 1615101

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 55

Group type: COMPARATOR
Intervention: Chlorpromazine and Haloperidol
Number of subjects: 55
Study: 6742743

Group type: EXPERIMENTAL
Intervention: Midazolam alone or in combination with pentazocine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 400

Group type: COMPARATOR
Intervention: Diazepam (Valium)
Number of subjects: 400
Study: 31204771

Group type: EXPERIMENTAL
Intervention: ∼3 g/d DHA
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: ∼3 g/d EPA
Number of subjects: 3

Group type: COMPARATOR
Intervention: Olive oil control
Number of subjects: 3
Study: 25226325

Group type: EXPERIMENTAL
Intervention: Training group (8 weeks of bicycle training)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 20
Study: 27055965

Group type: EXPERIMENTAL
Intervention: Sesame oil blend (20% sesame oil, 80% rice bran oil)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg/d)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Combination of sesame oil blend and nifedipine (20 mg/d)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (normotensives treated with sesame oil blend)
Number of subjects: 300
Study: 25194085

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for 15 days
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Phytotherapeutic agents for 30 days plus 15 days antibiotic treatment
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (Antibiotic treatment only for 15 days)
Number of subjects: 144
Study: 21680139

Group type: EXPERIMENTAL
Intervention: High-flex posterior cruciate-substituting (PS) design
Number of subjects: 29

Group type: COMPARATOR
Intervention: High-flex posterior cruciate-retaining (CR) design
Number of subjects: 29
Study: 20954287

Group type: EXPERIMENTAL
Intervention: PIK3CA mRNA in lymph node metastasis
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: PIK3CA protein expression
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: p-Akt protein
Number of subjects: 53
Study: 18043478

Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir (400/100 mg) twice a day
Number of subjects: 32

Group type: COMPARATOR
Intervention: saquinavir/ritonavir (1000/100 mg) twice a day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: darunavir/saquinavir/ritonavir (400/1000/100 mg) twice a day
Number of subjects: 32
Study: 16107961

Group type: EXPERIMENTAL
Intervention: Undiluted Lancy-Vaxina vaccine (n=56)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Diluted Lancy-Vaxina vaccine (n=56)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Previously vaccinated persons
Number of subjects: 112
Study: 12391348

Group type: EXPERIMENTAL
Intervention: SCS+PT
Number of subjects: 54

Group type: COMPARATOR
Intervention: SCS
Number of subjects: 54
Study: 9987155

Group type: EXPERIMENTAL
Intervention: Re-vaccination with vaccinia virus
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Re-vaccination at birth and again at 8 years old
Number of subjects: 99
Study: 7539852

Group type: EXPERIMENTAL
Intervention: Leuprolide (luteinizing hormone-releasing hormone agonist)
Number of subjects: 50
Study: 2305610

Group type: EXPERIMENTAL
Intervention: Glucose-free 2% lidocaine (80 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hyperbaric 5% lidocaine (80 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50